Jeff Yass’s Enliven Therapeutics ELVN Stock Holding History

Jeff Yass’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.06M	Sell	20,800 -92,500	-82%	-$3.93M	﹤0.01%	8061
2026 Q1	$4.44M	Buy	+113,300	New	+$3.14M	﹤0.01%	4454
2025 Q4	–	Sell	-59,000	Closed	-$1.21M	–	12639
2025 Q3	$1.21M	Buy	+59,000	New	+$1.19M	﹤0.01%	6906
2022 Q4	–	Sell	-18,075	Closed	-$165K	–	12714
2022 Q3	$165K	Buy	+18,075	New	+$107K	﹤0.01%	11112
2022 Q2	–	Sell	-3,650	Closed	-$27K	–	13130
2022 Q1	$27K	Sell	3,650 -50	-1%	-$330	﹤0.01%	12538
2021 Q4	$33K	Buy	3,700 +50	+1%	+$656	﹤0.01%	12716
2021 Q3	$60K	Buy	+3,650	New	+$75.8K	﹤0.01%	12284

Other funds holding ELVN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Jeff Yass's ELVN Position: Q2 2026 in Review

Jeff Yass reduced its Enliven Therapeutics (ELVN) stake by 84% in Q2 2026, selling an estimated $899K and leaving 3,993 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #11923.

Jeff Yass first reported a position in ELVN in Q3 2021 and has held it in 11 quarters since. The position peaked at $1.12M in Q2 2025. 209 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

Jeff Yass held 3,993 shares of Enliven Therapeutics worth $203K as of Q2 2026.
Jeff Yass sold 21,179 Enliven Therapeutics shares in Q2 2026, an estimated $899K.
Enliven Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11923 holding.
Jeff Yass first reported a position in Enliven Therapeutics in Q3 2021 and has held it in 11 quarters since.
Jeff Yass's Enliven Therapeutics position peaked at $1.12M in Q2 2025.
209 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.